The effect of transdermal oestrogen on bone, calcium-regulating hormones and liver in postmenopausal women.
Transdermal oestradiol, 100 micrograms/d, was used to treat 11 women suffering from postmenopausal symptoms. After 3 weeks therapy there was a significant rise in the plasma oestradiol into the premenopausal range and a significant fall in plasma FSH level and symptom score. Bone resorption, assessed by urinary excretion of calcium and hydroxyproline, decreased significantly while plasma alkaline phosphatase activity remained constant. There was a significant fall in plasma calcium and phosphate but the plasma concentrations of PTH, calcitonin and calcitriol and the urinary excretion of cAMP were unchanged. Plasma levels of vitamin D binding protein, albumin and globulin were unaltered, and blood pressure did not rise. These effects were similar to those found in postmenopausal women with oral ethinyloestradiol, 30 micrograms/d, (Selby et al., 1985), apart from those on plasma vitamin D binding protein, total calcitriol, albumin, globulin, tubular reabsorption of phosphate and blood pressure, changes which probably arise from a direct action of oral oestrogen on the liver.
D000279:Administration, Cutaneous; D001862:Bone Resorption / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects*; D002116:Calcitonin / Q000097:blood; D002118:Calcium / Q000097:blood; D004958:Estradiol / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D008099:Liver / Q000187:drug effects*; D008593:Menopause; D008875:Middle Aged; D010024:Osteoporosis / Q000097:blood / Q000188:drug therapy*; D010710:Phosphates / Q000097:blood
D010710:Phosphates; D004958:Estradiol; D005640:Follicle Stimulating Hormone; D002116:Calcitonin; D002118:Calcium